AACR 2026 – private biotechs score plenaries
Circle Pharma and Verismo feature in coveted sessions.
AACR 2026 – conjugates remain centre stage
Single, double and even triple-payload ADCs will be presented at the meeting.
Pfizer bags a hormone-sensitive win
Talapro-3 could help move Talzenna into earlier prostate cancer.
AACR 2026 – Merck’s VEGF bispecific reveal
First human data on MK-2010 are imminent.
Pfizer touts atirmociclib success
But this comes in second-line breast cancer, a use the group isn’t pursuing.
EAU 2026 – J&J strengthens its bladder hand
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
CCR8 promise and peril
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
CytomX looks good enough in colorectal cancer
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Mid-stage promise turns to pivotal bust for Immutep
Tacti-004 is terminated for futility, and Immutep crashes 89%.
